SCHEMBL5353374

SCHEMBL5353374

COc1cc(CCCCCCC=CCC=CCC=CCC=CCCCC(N)=O)ccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.61
TRPV1 Q8NER1 5/20 0.60
MAPT P10636 2/20 0.60
HPGD P15428 2/20 0.60
ALDH1A1 P00352 1/20 0.60
CYP1A2 P05177 3/20 0.60
CYP3A4 P08684 3/20 0.60
ALOX5 P09917 3/20 0.60
CYP2D6 P10635 2/20 0.60
LTA4H P09960 2/20 0.60
CYP2C8 P10632 2/20 0.60
CYP2C9 P11712 2/20 0.60
CYP2B6 P20813 2/20 0.60
CYP2C19 P33261 2/20 0.60
CYP2E1 P05181 1/20 0.60
CYP2A6 P11509 1/20 0.60
MEN1 O00255 1/20 0.55
TP53 P04637 1/20 0.55
MTOR P42345 1/20 0.55
KMT2A Q03164 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4155154 0.95 HTR1A (0.64) HTR1ATRPV1MAPTHPGDALDH1A1
SCHEMBL28378162 0.87 ALOX5 (0.66) HTR1ATRPV1HPGDALDH1A1CYP1A2
SCHEMBL11575857 0.87 ALOX5 (0.66) HTR1ATRPV1HPGDALDH1A1CYP1A2
SCHEMBL2683415 0.87 ALOX5 (0.66) HTR1ATRPV1HPGDALDH1A1CYP1A2
SCHEMBL906528 0.86 ALOX5 (0.67) HTR1ATRPV1ALDH1A1CYP1A2CYP3A4
SCHEMBL5723843 0.85 ALOX5 (0.66) HTR1ATRPV1ALDH1A1CYP1A2CYP3A4
SCHEMBL5351456 0.84 TAAR1 (0.66) HTR1ATRPV1MAPTHPGDCYP1A2
SCHEMBL5724212 0.80 ALOX5 (0.72) HTR1ATRPV1ALDH1A1CYP1A2CYP3A4
SCHEMBL6635889 0.80 TRPV1 (0.60) HTR1ATRPV1MAPTHPGDALDH1A1
SCHEMBL4733032 0.80 HTR1A (0.77) HTR1ATRPV1MAPTHPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7244767-B2 N-acylvanillinamide derivatives capable of activating peripheral cannabinoid receptors INNOVET ITALIA S.R.L. (IT) 2007-07-17 US claimed
US-20050065216-A1 Therapy for multiple sclerosis, psoriasis, urticaria; antiarthritic agents; incotinence; antitumor, anticancer agents INNOVET ITALIA S.R.L. (IT) 2005-03-24 US claimed
EP-1115392-B1 USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS INNOVET ITALIA SRL (IT) 2002-12-11 EP claimed
EP-1115392-B1 USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS INNOVET ITALIA SRL (IT) 2002-12-11 EP disclosed
EP-1115392-A2 USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS Innovet Italia S.r.l. (IT) 2001-07-18 EP disclosed
WO-2000016756-A2 USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS INNOVET ITALIA S.R.L. (IT) 2000-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065216-A1 Therapy for multiple sclerosis, psoriasis, urticaria; antiarthritic agents; incotinence; antitumor, anticancer agents CNR1, CNR2, GPR18 HTR1A 624/4885TRPV1 16/4885MAPT 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.